Neuronetics Draws Down Remaining $22.5 Million Available Under Credit Facility

MALVERN, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced today that it has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners, LLC (“SLR”).

“We are pleased to have successfully drawn down the remaining capital as part of our credit facility with SLR, which further bolsters our balance sheet in a non-dilutive manner and will support the ongoing execution of our strategy,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “Given the current challenging equity and debt capital markets environment, we felt it was prudent to strengthen our balance sheet in a cost-effective manner. The Company continues to believe that it can attain self-sustainability with the previous cash balance and that it can achieve cash flow break-even in Q4-2024 and on a full-year basis in 2025. This incremental capital should remove any doubt about the Company needing to access the equity markets. I want to thank SLR for their continued support of our vision to advance neurohealth therapies and drive the further adoption of NeuroStar Advanced Therapy for mental health.”

In April 2023, the Company amended its senior secured credit facilities with SLR, securing up to $60.0 million in borrowings. This facility includes three tranches of term loans, consisting of a “Term A Loan” of $35.0 million, a “Term B Loan” of $2.5 million, and a “Term C Loan” of $22.5 million. The Company has drawn down all $60.0 million available as part of this credit facility and the maturity date of the $60 million facility is now set for March 29, 2028.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.6 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.